The Food and Drug Administration (FDA) announced that Foradil Aerolizer (formoterol fumarate; Merck) has been discontinued. The decision to discontinue the product is business-related and not due to product safety or efficacy.

It is anticipated that the inventory will be exhausted and no longer distributed in or around January 2016, although inventory may be depleted earlier. Healthcare providers are encouraged to identify appropriate alternative treatments as soon as possible.

RELATED: Chronic Obstructive Pulmonary Disease Treatments

Foradil Aerolizer is indicated as adjunct for the maintenance treatment of asthma and in the prevention of bronchospasm in reversible obstructive airway disease (including nocturnal asthma); maintenance treatment of COPD-associated bronchospasm; and prevention of exercise-induced bronchospasm (EIB).

For more information call (888) 463-6332 or visit